Clinical trial
Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C…
NCT00121992 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00121992 |
|---|---|
| Title | Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment |
| Official title | Phase III Randomized Comparing Docetaxel, Doxorubicin and Cyclophosphamide (TAC) vs 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Patients With Negative Axillary Lymph Nodes |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel, 5-fluorouracil, Doxorubicin, Cyclophosphamide |
| Enrollment | 1,060 |
| Start date | Jul 1, 1999 |
| Primary completion | Dec 2, 2010 |
| Completion | Mar 6, 2013 |
| First posted | Jul 21, 2005 |
| Last update posted | Apr 4, 2023 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: